Nanoparticles Containing siRNA to Silence CD4 and CCR5 Reduce Expression of These Receptors and Inhibit HIV-1 Infection in Human Female Reproductive Tract Tissue Explants

Abstract

Human Immunodeficiency Virus-type 1 (HIV-1) binds to CD4 and CCR5 receptors on target cells in the human female reproductive tract. We sought to determine whether reducing levels of messenger RNA (mRNA) transcripts that encode these receptors in female reproductive tract cells could protect mucosal tissue explants from HIV-1 infection. Explants prepared from the endometrium, endocervix, and ectocervix of hysterectomy tissues from HIV-1 sero-negative women were exposed to nanoparticles containing CD4-and CCR5-specific short-interfering RNA (siRNA) sequences. Explants were then exposed two days later to HIV-1, and HIV-1 reverse transcripts were measured five days post-infection. Explants treated with nanoparticles containing CD4-and CCR5-specific siRNA showed reduced levels of CD4 and CCR5 transcripts, and significantly lower levels of HIV-1 reverse transcripts compared to those treated with an irrelevant siRNA. In female reproductive tract explants and in peripheral blood cell cultures, siRNA transfection induced the secretion of IFN-alpha (IFN-α), a potent antiviral cytokine. In female mice, murine-specific Cd4-siRNA nanoparticles instilled within the uterus significantly reduced murine Cd4 transcripts by day 3. Our findings demonstrate that siRNA nanoparticles reduce expression of HIV-1 infectivity receptors in human female reproductive tract tissues and also inhibit HIV-1 infection. Murine studies demonstrate that nanoparticles can penetrate the reproductive tract tissues in vivo and silence gene expression. The induction of IFN-α after siRNA transfection can potentially contribute to the antiviral effect. These findings support the therapeutic development of nanoparticles to deliver siRNA molecules to silence host cell receptors in the female reproductive tract as a novel microbicide to inhibit mucosal HIV-1 transmission.

Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection

“…Microbicide developers seek more durable, low toxicity vehicles that provide acceptable vaginal retention [12, 13, 20, 29, 30]. An ideal delivery system would encapsulate agents at high density (to minimize the amount of vehicle that must be administered), protect the agents from enzymatic degradation, have the ability to target specific cell types, exhibit sustained release, and be maintained in the vaginal tissues for long time periods [13, 18, 20, 30-32].…”

Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy

“…31 Their goal was to prevent HIV-1 infection in the human female reproductive tract by knocking down the CD4 and CCR5 receptors, which are essential for HIV infection. The carrier used is INTERFERin (Genesee Scientific, San Diego, CA, USA), which is a nonliposomal cationic amphiphile transfection reagent.…”